Small US biotech DNDN, is about to have its trial results...

Small US biotech DNDN, is about to have its trial results published in the Journal of Clinical Oncology in the next few days. They have a prostate(AIPC) cancer vaccine that extends survival over the best current treatment, which is the chemo Taxotere, while eliminating the chemo side effects. Building a plant in NJ to service the US market. Trials are complete. Yet to be approved by the FDA.